Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

NGNE 11.18.2024

Full Press ReleaseSEC FilingsOur NGNE Tweets

About Gravity Analytica

Recent News

  • 11.19.2024 - Stifel 2024 Healthcare Conference
  • 11.18.2024 - Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
  • 11.18.2024 - Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

Recent Filings

  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - EX-99.1 EX-99.1
  • 12.18.2024 - 424B3 Prospectus [Rule 424(b)(3)]

NEW YORK--(BUSINESS WIRE)--Nov. 18, 2024--Neurogene Inc.(Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluatingNGN-401gene therapy for the treatment of Rett syndrome.

As previously disclosed, onNovember 11,2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who receivedNGN-401at a dose of 3E15 vg (high-dose cohort). This participant, who was dosed onNovember 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response that has been reported with systemic exposure to high doses of AAV. Hyperinflammatory syndromes are associated with aberrant cytokine release and include hemophagocytic lymphohistiocytosis (HLH) and multisystem inflammatory syndrome. The participant is in critical condition, and the case is continuing to evolve.

“We are deeply saddened for the family. While no words could possibly provide comfort to her family, we ask the Rett syndrome community to join us in sending heartfelt thoughts to her family, friends and the dedicated clinicians who are caring for her,” saidRachel McMinn, Ph.D., Founder and Chief Executive Officer of Neurogene. “The safety of the participants in our clinical trial is and remains our foremost priority as we work to find solutions for this devastating disease.”

In a commitment to full transparency with theU.S. Food and Drug Administration(FDA), Neurogene proactively engaged with the FDA under the START program following the Company’s notification of the SAE. The FDA completed a review of the safety data forNGN-401and allowed Neurogene to proceed with the Phase 1/2 trial using the 1E15 vg dose (low-dose cohort). Neurogene paused further use of the 3E15 vg dose (high-dose cohorts) upon initial notification of the SAE and does not plan to enroll any further participants at the 3E15 vg dose level.

To date, there have been no other treatment-related SAEs in the clinical trial, including in the five participants who received the 1E15 vg dose (low-dose cohort) and in the first two participants who received the 3E15 vg dose (high-dose cohort) ofNGN-401. All treatment-related AEs in the 1E15 vg cohort (low-dose cohort) have been Grade 1 (mild). Most treatment-related AEs are known potential risks of AAV, have been responsive to steroids, and have resolved or are resolving. There have been no signs or symptoms indicative of MeCP2 overexpression toxicity. In addition, there have been no intracerebroventricular (ICV) procedure-related AEs.

Neurogene no longer anticipates completing enrollment in the 1E15 vg cohort (low-dose cohort) ofNGN-401in the fourth quarter of 2024 as the Company updates the protocol to reflect the discontinuation of the 3E15 vg dose.

About Neurogene

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company’s novel and proprietary EXACTTM transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility inHouston, Texas. CGMP production ofNGN-401was conducted in this facility and will support pivotal clinical development activities. For more information, visitwww.neurogene.com.

Cautionary Note Regarding Forward-Looking Statements

Statements in this press release are made as of the date of this press release. Neurogene does not undertake any obligation to make any updates to these statements to reflect events that occur or circumstances that arise after the date of this press release, except as may be required under applicableU.S.securities law.

Statements in this press release which are not historical in nature are intended to be, and hereby are identified as, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current expectations and beliefs of the management of Neurogene, as well as assumptions made by, and information currently available to, management of Neurogene, including, but not limited to, statements regarding: the safety ofNGN-401, including the safety of AAV as a component ofNGN-401and the safety of any specific cohort of the trial; the therapeutic potential and utility, efficacy and clinical benefits ofNGN-401; Neurogene’s ability to identify any potential indicators of predisposition to the serious adverse event (SAE) experienced by the third participant of the high-dose cohort; information relating to an understanding of the nature of the SAE that occurred in the high dose cohort of theNGN-401trial for Rett syndrome; trial designs, clinical development plans and timing forNGN-401, including anticipated timing of additional dosing of participants in the Company’sNGN-401Phase 1/2 trial for Rett syndrome; the status of participants in our clinical trials, including those that have in the past and may in the future experience safety-related events; and expected future interactions with or positions of the FDA; . Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “on track,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks, uncertainties and assumptions that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results and many of which are outside of Neurogene’s control. Such risks, uncertainties and assumptions include, among other things: risks related to the timing and success of enrolling patients in our Phase 1/2 clinical trial ofNGN-401for the treatment of Rett syndrome, including the potential impact of the SAE on the decision by care givers on whether to enroll participants in the clinical trial; the expected timing and results of dosing of patients in ourNGN-401clinical trial; the potential for negative impacts to participants in the Phase 1/2 clinical trial ofNGN-401for the treatment of Rett syndrome; the risk that we may not be able to report our data on the predicted timeline; risks related to our ability to obtain regulatory approval for, and ultimately commercialize, our product candidates, includingNGN-401; our ability to accurately characterize safety events that may arise in the course of our clinical trials; and other risks and uncertainties identified under the heading "Risk Factors" included in our Annual Report on Form 10-K for the year endedDecember 31, 2023, filed with theSecurities and Exchange Commission(“SEC”) onMarch 18, 2024, or our Quarterly Report on Form 10-Q for the quarter endedJune 30, 2024, and other filings that the Company has made and may make with theSECin the future. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that the contemplated results of any such forward-looking statements will be achieved. Forward-looking statements in this communication speak only as of the day they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by applicable law, Neurogene undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

This communication contains hyperlinks to information that is not deemed to be incorporated by reference into this communication.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241118334218/en/

Company:Cara MayfieldVice President, Corporate Affairscara.mayfield@neurogene.com

Investor:Melissa ForstArgot PartnersNeurogene@argotpartners.com

Source:Neurogene Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com